건강보험 청구자료를 활용한 약물관련 악골괴사의 국내 현황 및 비용 분석

Although Medication-Related Osteonecrosis of the Jaw (MRONJ) does not usually occur, the use of drugs that may cause MRONJ is increasing and there is no research reported about its cost and the perception of MRONJ is low in Korea. So here we analyzed the current disease status, such as occurrence and duration, and the cost of treatment of MRONJ in Korea. It was analyzed by the National Health Insurance Service sample cohort 2.0DB data. Patients were included who diagnosed and treated with ‘Osteonecrosis due to drugs (ICD-10: M87.1)’ or ‘Inflammatory conditions of jaws (ICD-10: K10.2)’ after the less than three years from the last dose of drugs. A total of 183 MRONJ patients were identified. The most frequently administered Bone-Modifying Agents were Alendronate, Risedronate, and Ibandronate. From 2002 to 2015, the proportion of MRONJ in the total number of prescribed patients was between 0.2% and 0.9%. The billing costs for MRONJ per patient was KRW 934,422. The highest cost claim was Surgery of Osteomyelitis of Mandible or Maxilla. The total cost of medical, non-medical and indirect costs was KRW 1,891,808 per patient. Through this research, it was found that the cost of treatment of MRONJ was high, and it was possible to analyze the current status and characteristics of MRONJ in Korea.